However, on the other hand, RT can also result in an increased frequency of circulating tumor-specific T cells in the CD8+ population, as observed in colorectal and prostate cancer patients [36], and the frequency of circulating HLA-DRhi monocytes is a strong predictor of progression-free and overall survival in response to therapy in stage IV melanoma patients [37]. The gene discussed is CD8A; the disease is prostate carcinoma.